Repligen Corp. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Repligen Corp. has filed its 2023 10-K annual report detailing financial performance and business operations.</b>

AI Summary

REPLIGEN CORP (RGEN) filed a Annual Report (10-K) with the SEC on February 22, 2024. Repligen Corp. filed its 10-K report for the fiscal year ending December 31, 2023. The filing includes details on various financial instruments, including convertible senior notes due in 2028 and 2024. The company's business address is located at 41 Seyon Street, Building 1, Suite 100, Waltham, MA 02453. Key dates and events related to financial reporting and business operations are referenced throughout the document. The report covers the fiscal year from January 1, 2023, to December 31, 2023.

Why It Matters

For investors and stakeholders tracking REPLIGEN CORP, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Repligen's financial health, operational activities, and strategic initiatives for the fiscal year 2023, which is crucial for investors to assess the company's performance and future outlook. The detailed financial information, including notes on convertible senior notes and various business segments, allows stakeholders to understand the company's financial structure, potential risks, and growth drivers.

Risk Assessment

Risk Level: medium — REPLIGEN CORP shows moderate risk based on this filing. The filing is a standard 10-K, which is a comprehensive report but does not contain new, unexpected, or significantly negative information that would elevate the risk beyond medium.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Repligen's performance and strategic positioning.

Key Numbers

• 20231231 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
• 20240222 — Filing Date (FILED AS OF DATE)
• 121 — Public Document Count (PUBLIC DOCUMENT COUNT)
• 000-14656 — SEC File Number (SEC FILE NUMBER)

Key Players & Entities

• REPLIGEN CORP (company) — FILER
• 0000730272 (company) — CENTRAL INDEX KEY
• 2836 (company) — STANDARD INDUSTRIAL CLASSIFICATION
• DE (company) — STATE OF INCORPORATION
• 41 SEYON STREET (company) — BUSINESS ADDRESS
• WALTHAM (company) — BUSINESS ADDRESS CITY
• MA (company) — BUSINESS ADDRESS STATE
• 02453 (company) — BUSINESS ADDRESS ZIP

FAQ

Industry Context

Repligen Corporation operates in the life sciences industry, focusing on bioprocessing technologies and diagnostics.

Regulatory Implications

The filing is a standard Form 10-K, adhering to SEC regulations for annual financial reporting by public companies.

What Investors Should Do

1. Review Repligen's financial statements for the fiscal year 2023.
2. Analyze the notes to the financial statements for details on debt and other financial instruments.
3. Examine any disclosed risk factors to understand potential challenges.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-02-22: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the 2023 10-K filing, providing the latest annual financial and operational data for Repligen Corp.

Key Financial Figures

• $0.01 — h registered Common Stock , par value $0.01 per share RGEN The Nasdaq Global Se

Filing Documents

• rgen-20231231.htm (10-K) — 3949KB
• rgen-ex10_5.htm (EX-10.5) — 48KB
• rgen-ex19_1.htm (EX-19.1) — 129KB
• rgen-ex21_1.htm (EX-21.1) — 21KB
• rgen-ex23_1.htm (EX-23.1) — 6KB
• rgen-ex31_1.htm (EX-31.1) — 12KB
• rgen-ex31_2.htm (EX-31.2) — 12KB
• rgen-ex32_1.htm (EX-32.1) — 14KB
• rgen-ex97_1.htm (EX-97.1) — 42KB
• img33618189_0.jpg (GRAPHIC) — 47KB
• 0000950170-24-018809.txt (&nbsp;) — 19293KB
• rgen-20231231.xsd (EX-101.SCH) — 2683KB
• rgen-20231231_htm.xml (XML) — 4102KB

Forward-looking Statements

Forward-looking Statements 1 PART I 2 Item 1.

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 18 Item 1B. Unresolved Staff Comments 34 Item 1C. Cybersecurity 34 Item 2.

Properties

Properties 35 Item 3.

Legal Proceedings

Legal Proceedings 35 Item 4. Mine Safety Disclosures 35 PART II 36 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 36 Item 6. [Reserved ] 38 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 55 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 55 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 56 Item 9A.

Controls and Procedures

Controls and Procedures 56 Item 9B. Other Information 59 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 59 PART III 60 PART IV 61 Item 15. Exhibits and Financial Statement Schedules 61 Item 16. 10-K Summary 64

SIGNATURES

SIGNATURES 65 Summary of the Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following: Our product revenue may be negatively impacted by a number of factors, including without limitation, competition in the bioprocessing market, our historical reliance on a limited number of large customers, our ability to develop or acquire additional bioprocessing products in the future, our ability to manufacture our bioprocessing products sufficiently and timely, supply chain issues and/or disruption, and our ability to effectively penetrate the bioprocessing products market. We rely on a limited number of suppliers or, for certain of our products, one supplier, and we may not be able to find replacements or immediately transition to alternative suppliers, which could have a material adverse effect on our financial condition, results of operations and reputation. The market may not be receptive to our new bioprocessing products upon their introduction. If our products do not perform as expected or the reliability of the technology on which our products are based is questioned, we could experience lost revenue, delayed or reduced market acceptance, increased cost and damage to our reputation. If we are unable to manufacture our products in sufficient quantities and in a timely manner, our operating results will be harmed, our ability to generate revenue could be diminished and our gross margin may be negatively impacted. Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies. Our results of operations could be negatively affected by potential fluctuations in foreign currency exchange rates. Our corporate restructuring and the associated headcount reduction may not result in anticipate

B USINESS

ITEM 1. B USINESS The following discussion of our business contains forward-looking statements that involve risks and uncertainties. When used in this report, the words "intend," "anticipate," "believe," "estimate," "plan" and "expect" and similar expressions as they relate to us are included to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements and are a result of certain factors, including those set forth under "Risk Factors" and elsewhere in this Annual Report on Form 10-K ("Form 10-K"). References throughout this Form 10-K to "Repligen Corporation", "Repligen", "we", "us", "our", or the "Company" refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates. Overview Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies ("mAbs") and mAb derivatives, recombinant proteins, vaccines, and cell and gene therapies ("C&GT") – that are improving human health worldwide. Increasingly, our technologies are being implemented to overcome challenges in processing plasmid DNA (a starting material for the production of mRNA) and gene delivery vectors such as lentivirus and adeno-associated viral vectors.

View Full Filing

View this 10-K filing on SEC EDGAR